Ernexa Therapeutics Inc 8-K, filed Jun 20, 2023
Ernexa Therapeutics Inc. (ERNA)
8-K
2023-06-20
For: 2023-06-16
View Original
Added on
April 06, 2026
About this 8-K
Ernexa Therapeutics Inc filed this 8-K on June 20, 2023, reporting on events of June 16, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 16, 2023
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
||
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212 ) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
On June 16, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “Company”), held its 2023 Annual Meeting of Stockholders (the “Annual
Meeting”). The final voting results for the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are as follows:
Proposal 1: Election of five directors to the Board of Directors of the Company
to hold office until the Company’s 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified:
|
Director
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
|||
|
Charles Cherington
|
2,731,140
|
49,320
|
769,743
|
|||
|
Matthew Angel
|
2,761,115
|
19,345
|
769,743
|
|||
|
Gregory Fiore
|
2,687,900
|
92,560
|
769,743
|
|||
|
William Wexler
|
2,746,291
|
34,169
|
769,743
|
|||
|
Nicholas J. Singer
|
2,757,575
|
22,885
|
769,743
|
Proposal 2: Ratification of the appointment of Grant Thornton LLP as the
Company’s independent registered public accounting firm for the 2023 fiscal year:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
3,520,765
|
23,287
|
6,151
|
—
|
Proposal 3: Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to potentially issuance and sell more than 20% of the Company’s outstanding common stock pursuant to its purchase agreement with Lincoln Park Capital, LLC:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
2,751,635
|
26,798
|
2,027
|
769,743
|
Proposal 4: Approval of an amendment to the Company’s Restated 2020 Stock Incentive Plan to increase the number of shares reserved for issuance from 680,599 shares to 980,599 shares:
|
Votes
For
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
|||
|
2,615,319
|
160,415
|
4,726
|
769,743
|
No other matters were considered or voted upon at the Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
Eterna Therapeutics Inc.
|
||
|
Dated: June 20, 2023
|
By:
|
/s/ Sandra Gurrola |
|
Sandra Gurrola, Vice President of Finance
|
||